Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22456184
Oliveira SM, et al. (2012) AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circ Res 110, 1192-201 22456184
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T172-p - AMPKA2 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia increase
acadesine increase
compound_C acadesine inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  activity, induced
Comments:  increased cardiac contractility and Ca2+ sensitivity

S23-p - TNNI3 (human)
Modsite: PAPIRRRssNyRAyA SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): S23‑p, TNNI3 (mouse): S23‑p, TNNI3 (rat): S23‑p, TNNI3 (rabbit): S22‑p, TNNI3 (dog): S23‑p, TNNI3 (cow): S24‑p
Characterization
Methods used to characterize site in vivo [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  tissue
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AMPKA1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
acadesine no change compared to control
acadesine, compound_C no change compared to control

S24-p - TNNI3 (human)
Modsite: APIRRRssNyRAyAt SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): S24‑p, TNNI3 (mouse): S24‑p, TNNI3 (rat): S24‑p, TNNI3 (rabbit): S23‑p, TNNI3 (dog): S24‑p, TNNI3 (cow): S25‑p
Characterization
Methods used to characterize site in vivo [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  tissue
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AMPKA1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
acadesine no change compared to control
acadesine, compound_C no change compared to control

S42-p - TNNI3 (human)
Modsite: AKKKskIsAsRKLQL SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): S42‑p, TNNI3 (mouse): S43‑p, TNNI3 (rat): S43‑p, TNNI3 (rabbit): S42‑p, TNNI3 (dog): S43‑p, TNNI3 (cow): S44‑p

S44-p - TNNI3 (human)
Modsite: KKskIsAsRKLQLKt SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): S44‑p, TNNI3 (mouse): S45‑p, TNNI3 (rat): S45‑p, TNNI3 (rabbit): S44‑p, TNNI3 (dog): S45‑p, TNNI3 (cow): S46‑p

T143-p - TNNI3 (human)
Modsite: RGKFKRPtLRRVrIs SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): T143‑p, TNNI3 (mouse): T144‑p, TNNI3 (rat): T144‑p, TNNI3 (rabbit): T143‑p, TNNI3 (dog): T144‑p, TNNI3 (cow): T145‑p

S150-p - TNNI3 (human)
Modsite: tLRRVrIsADAMMQA SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): S150‑p, TNNI3 (mouse): S151‑p, TNNI3 (rat): S151‑p, TNNI3 (rabbit): S151‑p, TNNI3 (dog): S151‑p, TNNI3 (cow): S152‑p
Characterization
Methods used to characterize site in vivo [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  tissue
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AMPKA1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE AMPKA1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia increase
acadesine increase
compound_C acadesine inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  activity, induced
Comments:  increased cardiac contractility and Ca2+ sensitivity